Celanese Corporation (CE) recently announced the launch of Glaukos Corporation's iDose TR. This uses CE's VitalDose EVA to offer continuous medication release for the treatment of glaucoma.The majority of glaucoma and ocular hypertension patients do not adhere to topical drug regimens due to complex dosing courses, adverse effects and eye-drop sensitivity. Sustained delivery of medications is a significant technique for addressing noncompliance and enhancing treatment results. With iDose TR and VitalDose EV ...